Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference16 articles.
1. Seronegative Sjögren Syndrome: A Forgotten Entity?
2. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study;Fisher;Lancet Rheumatol,2020
3. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial;Bowman;Lancet,2022
4. Dörner T , Szántó A , Tseng J , Remibrutinib (LOU064) in Sjögren’s syndrome: safety and efficacy results from a 24-week placebo-controlled proof-of-concept study [abstract]. Arthritis Rheumatol 2022;74 Suppl 9.
5. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome